Astal Laboratories Limited

BSE: ASTALLTD · Pharmaceuticals

52W Range₹60 ₹103

Limited coverage

We are not actively covering this company or have limited coverage today. Click to request coverage.

Snapshot

Unlock Astal Laboratories Limited's vital signs

Growth · Profitability · Valuation · Strength · Conviction

Company Overview

Business

Astral Limited is a leading Indian manufacturer specialising in plumbing, drainage systems, adhesives, and sealants. The company has diversified its portfolio to include bathware, paints, and sanitaryware, leveraging a robust pan-India manufacturing and distribution network.

Business Model

The company generates revenue through the manufacturing and sale of building materials, primarily piping solutions and adhesive products. It operates through a widespread distribution network that serves both residential and industrial construction sectors.

Growth Outlook

Growth is driven by the expansion into new categories such as paints and sanitaryware, alongside the continued scaling of its established piping and adhesives businesses. The company aims to leverage its strong brand equity and distribution reach to capture a larger share of the Indian building materials market.

Key Risks

  • Raw Material Price Volatility. Fluctuations in the prices of petrochemical derivatives like PVC and CPVC resins can significantly impact operating margins.
  • Cyclicality of Real Estate. The company's performance is closely tied to the health of the Indian construction and real estate sectors.
  • Intense Market Competition. The building materials sector is highly competitive, with pressure from both established players and unorganised local manufacturers.
  • Integration Risk. Successful scaling of recently acquired businesses in the paints and sanitaryware segments is critical for long-term value creation.

Start your research today

Unlock AI insights, financials, peers and live data on Astal Laboratories Limited and 5,000+ companies — free.

Start your research

Key Metrics

REVENUE

₹156 Cr

TTM · standalone

+142.9%YoY

NET PROFIT

₹8 Cr

TTM · standalone

-9.0%YoY

EPS

₹7.00

TTM · standalone

-23.0%YoY

RETURN ON EQUITY

7.5%

TTM · standalone

-26.2 ppYoY

RETURN ON CAPITAL EMPLOYED

11.2%

TTM · standalone

-36.0 ppYoY

P/E

11.7x

Q4 FY26 · standalone

11.7 vs -254.7x5Y avg

EV/EBITDA

23.0x

Q4 FY26 · standalone

23.0 vs 85.8x5Y avg

EBITDA MARGIN

8.3%

TTM · standalone

-11.8 ppYoY

Peers · Pharmaceuticals

CompanyMkt CapP/EEV/EBITDARev Gr YoYEBITDA MgnROEROCE1Y Return
Astal Laboratories LimitedASTALLTD
₹345 Cr11.2527.50142.9%8.3%7.5%11.2%-9.0%
Albert DavidALBERTDAVD
₹513 Cr22.7313.4811.4%11.0%5.8%7.5%+12.1%
Jenburkt Pharmaceuticals LimitedJENBURPH
₹463 Cr13.318.4632.0%17.6%23.2%-4.3%
Haleos Labs LimitedHALEOSLABS
₹452 Cr28.6012.72-3.1%13.6%7.4%10.3%
TranschemTRANSCHEM
₹424 Cr98.7668.07-100.0%177.7%5.3%7.0%+592.6%
Medicamen BiotecMEDICAMEQ
₹338 Cr33.5915.5324.7%11.3%4.1%6.2%-27.9%

As of Q4 FY26

Financials